15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Rxsight Inc, 1 rate it Buy or better, 5 sit at Hold, and 2 rate it Sell or worse, a hold consensus. Targets span $6.30 to $11.00, a moderate spread. The average target of $8.60 sits 36% above the current $6.32. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.18 next quarter toward $-0.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Hold
Strong Buy00%
Buy113%
Hold563%
Sell225%
Strong Sell00%
Based on 8 analysts giving stock ratings to Rxsight Inc.
As of Sep, 1 of 8 firms rate RXST a Buy (5 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
RXST EPS & revenue forecast
EPS · NEXT QUARTER
$0.18
Range $-0.13 – $0.40 · 5 analysts · -711% YoY
Next period, 5 analysts expect Rxsight Inc to earn $0.18 a share (range $-0.13 – $0.40), versus $-0.03 a year earlier. Full-year consensus is $-0.27, growing to $-0.70 the year after.
REVENUE · NEXT QUARTER
$55.4M
Range $29.0M – $61.1M · 5 analysts · +70% YoY
Revenue is expected to reach $55.4M (range $29.0M – $61.1M), +69.9% year-over-year. Full-year consensus is $147.3M, rising to $149.4M next year.
Top analysts covering Rxsight Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RXST.
#1
David Saxon
Needham · Rank #347
Buy
$11.00+74.1% to target
Overall win rate
32%
+ Follow
#2
LB
Larry Biegelsen
Wells Fargo
Hold
$9.00+42.4% to target
Coverage
—
+ Follow
#3
TS
Tom Stephan
Stifel
Hold
$7.00+10.8% to target
Coverage
—
+ Follow
#4
Adam Maeder
Piper Sandler
Hold
$10.00+58.2% to target
Coverage
—
+ Follow
#5
Danielle Antalffy
UBS
Hold
$9.00+42.4% to target
Coverage
—
+ Follow
RXST stock forecast FAQ
What is RXST's average 12-month price target?+
The 8 analysts with a live target average $8.60 for Rxsight Inc over the next 12 months, ranging from a $11.00 high to a $6.30 low.
Is RXST stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 8 analyst ratings, 1 are Buy or Strong Buy, 5 are Hold, and 2 are Sell or Strong Sell.
What are the highest and lowest price targets for RXST?+
The Street-high target is $11.00 (Needham), and the Street-low is $6.30 (UBS). The average of all 8 active targets is $8.60.
How many Wall Street analysts cover RXST?+
8 analysts have an active rating on Rxsight Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering RXST?+
Among analysts who currently cover RXST, David Saxon of Needham has the strongest overall Quantellect track record (Rank #347). Their current call is Buy with a $11.00 target.
What is Rxsight Inc's projected EPS for next quarter?+
The consensus estimate is $0.18 per share (range $-0.13 – $0.40) across 5 analysts. Full-year EPS is projected at $-0.27, rising to $-0.70 the following year.
How much revenue is Rxsight Inc expected to report next quarter?+
Consensus revenue is $55.4M (range $29.0M – $61.1M). Full-year revenue is projected at $147.3M, growing to $149.4M next year.
Have analysts been upgrading or downgrading RXST lately?+
As of Sep, 1 of 8 firms rate RXST a Buy (5 Hold, 2 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RXST calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
UBS
